Search / Trial NCT00001986

1-Octanol to Treat Essential Tremor

Launched by NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE (NINDS) · Dec 9, 2002

Trial Information

Current as of December 26, 2024

Completed

Keywords

Alcohol Octanol Treatment Tremor

ClinConnect Summary

Essential tremor (ET) is the most common movement disorder; however, there is currently no satisfactory drug treatment. The neural mechanisms underlying ET remain unknown. One of the prevalent hypotheses is that ET is a result of a defective mechanism that normally dampens the natural oscillations of inferior olive (IO) neurons whose intrinsic oscillatory activity is attributed to the presence of low threshold calcium channels (LTCC). 1-Octanol is known to inhibit LTCC of olivary neurons and was found to reduce the tremor induced in rats with harmaline, an alkaloid known to hyperpolarize IO...

Gender

ALL

Eligibility criteria

  • Patients with essential tremor affecting the upper limbs who are 21 years of age or older.
  • Patients who are not taking medications for essential tremor or any other medical condition for at least 2 weeks.
  • Patients who have not consumed alcohol or cold medications containing alcohol for at least 24 hours prior to the day of the study.
  • Women must not be pregnant or lactating. Women of childbearing age must use birth control while participating in this study.
  • Patients must not have any neurological disease other than tremor (e.g., Parkinson's disease).
  • Patients must not have evidence of thyroid, liver, kidney or chronic lung disease.

About National Institute Of Neurological Disorders And Stroke (Ninds)

The National Institute of Neurological Disorders and Stroke (NINDS) is a leading component of the National Institutes of Health (NIH), dedicated to advancing our understanding of the brain and nervous system through innovative research. NINDS sponsors and conducts clinical trials aimed at developing effective treatments and improving patient outcomes for a wide range of neurological disorders, including stroke, epilepsy, multiple sclerosis, and neurodegenerative diseases. By fostering collaboration among researchers, healthcare providers, and patient communities, NINDS plays a pivotal role in transforming scientific discoveries into clinical applications, ultimately enhancing the quality of life for individuals affected by neurological conditions.

Locations

Bethesda, Maryland, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials